Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Sanofi's Infilbray wins first approval for neurological symptoms of Gaucher

EndpointsView source article

Part of story

Sanofi wins first FDA approval for neurological symptoms of Gaucher disease

The FDA approved Sanofi's Infilbray, a brain-penetrating small molecule that is the first therapy cleared in the US to treat the neurological symptoms of Gaucher disease type 3.

Nov 19, 2026·3 sourcesRare diseasesPharmaceutical IndustryNeurodegenerationFDA drug approvalDrug Policy, Pricing & ApprovalClinical trialsGenetic diseases
Sanofi wins first FDA approval for neurological symptoms of Gaucher disease
00

Other sources for this story

MedCity News

FDA Approval for Sanofi Drug Marks an Important First in Rare Disease - MedCity News

BioPharma Dive

Sanofi gains FDA clearance for Gaucher disease pill